Cargando…

Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer

SIMPLE SUMMARY: Response evaluation following neoadjuvant chemotherapy for gastric cancer has been widely debated. Following a full course of preoperative cycles, response evaluation can guide the vigor in delivering postoperative chemotherapy, indicate for whom a shift in regimen following a later...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandø, Alina Desiree, Fougner, Reidun, Røyset, Elin Synnøve, Dai, Hong Yan, Grønbech, Jon Erik, Bringeland, Erling Audun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10137129/ https://www.ncbi.nlm.nih.gov/pubmed/37190246 http://dx.doi.org/10.3390/cancers15082318

Ejemplares similares

The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study
por: Sandø, Alina Desiree, et al.
Publicado: (2021)

Hypergastrinemia is associated with an increased risk of gastric adenocarcinoma with proximal location: A prospective population‐based nested case‐control study
por: Ness‐Jensen, Eivind, et al.
Publicado: (2020)

Subtle Protective Roles of Clusterin in Gastric Metaplasia After Acute Oxyntic Atrophy
por: Vange, Pål, et al.
Publicado: (2018)

Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial - 1 (NorPACT-1)) – study protocol for a national multicentre randomized controlled trial
por: Labori, Knut Jørgen, et al.
Publicado: (2017)

Gastric Cancers Missed at Upper Endoscopy in Central Norway 2007 to 2016—A Population-Based Study
por: Beck, Marianne, et al.
Publicado: (2021)

Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer
por: Hu, Shen-Bao, et al.
Publicado: (2019)

Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal
por: Gervaso, Lorenzo, et al.
Publicado: (2021)

Simultaneous Resection of Primary Colorectal Cancer and Synchronous Liver Metastases: Contemporary Practice, Evidence and Knowledge Gaps
por: Kleive, Dyre, et al.
Publicado: (2021)

Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series
por: Hadzitheodorou, Christina, et al.
Publicado: (2017)

Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
por: Tian, Yuan, et al.
Publicado: (2021)

Neoadjuvant PD‐1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung
por: Feng, Yuan, et al.
Publicado: (2021)

Survival after neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: A meta‐analysis
por: Fan, Mengying, et al.
Publicado: (2015)

A case study of combined neoadjuvant chemotherapy and neoadjuvant immunotherapy in resectable locally advanced esophageal cancer
por: Dai, Huiru, et al.
Publicado: (2022)

Neoadjuvant Treatment for Resectable and Borderline Resectable Pancreatic Cancer: Chemotherapy or Chemoradiotherapy?
por: Versteijne, Eva, et al.
Publicado: (2022)

Resection of colorectal liver metastases following neoadjuvant chemotherapy
por: Chiappa, A, et al.
Publicado: (2007)

Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma
por: Borg, David, et al.
Publicado: (2018)

Evaluation of neoadjuvant immunotherapy plus chemotherapy in Chinese surgically resectable gastric cancer: a pilot study by meta-analysis
por: Xu, Hao, et al.
Publicado: (2023)

The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer
por: Sun, Juan, et al.
Publicado: (2021)

Long-term survival results of patients with locally advanced gastric cancer and pathological complete response after neoadjuvant chemotherapy and resection
por: Wang, Tongbo, et al.
Publicado: (2020)

Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection
por: Sun, Yongkun, et al.
Publicado: (2017)

FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer
por: Zhang, Shun, et al.
Publicado: (2020)

Neoadjuvant PD-1 blockade combined with chemotherapy is not superior to neoadjuvant chemotherapy alone in resectable locally advanced esophageal carcinoma
por: Cheng, Daoan, et al.
Publicado: (2023)

Code-Free Development and Deployment of Deep Segmentation Models for Digital Pathology
por: Pettersen, Henrik Sahlin, et al.
Publicado: (2022)

Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases
por: Zhu, Dexiang, et al.
Publicado: (2014)

Profound gene expression changes in the epithelial monolayer of active ulcerative colitis and Crohn’s disease
por: Sæterstad, Siri, et al.
Publicado: (2022)

Is neoadjuvant chemotherapy necessary for patients with initially resectable colorectal liver metastases in the era of effective chemotherapy?
por: Son, Sang-Yong, et al.
Publicado: (2011)

Perioperative versus total neoadjuvant chemotherapy in gastric cancer
por: Yang, Jessica, et al.
Publicado: (2023)

Outcomes of Neoadjuvant Chemoradiation With and Without Systemic Chemotherapy in Resectable and Borderline Resectable Pancreatic Adenocarcinoma
por: Trinh, Katherine V., et al.
Publicado: (2020)

What is the optimal number of neoadjuvant chemotherapy cycles for resectable colorectal liver oligometastases?
por: Chen, Qichen, et al.
Publicado: (2021)

Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis
por: Chen, Jiuzhou, et al.
Publicado: (2022)

Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes
por: Liu, Yi, et al.
Publicado: (2018)

Marginal resection for osteosarcoma with effective neoadjuvant chemotherapy: long-term outcomes
por: Xu, Ming, et al.
Publicado: (2014)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Bacterial Mucosa-associated Microbiome in Inflamed and Proximal Noninflamed Ileum of Patients With Crohn’s Disease
por: Olaisen, Maya, et al.
Publicado: (2020)

Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?
por: Reddavid, Rossella, et al.
Publicado: (2018)

Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer
por: Tong, Xie, et al.
Publicado: (2023)

Effect of neoadjuvant chemotherapy combined with hyperthermic intraperitoneal perfusion chemotherapy on advanced gastric cancer
por: CUI, HAI-BIN, et al.
Publicado: (2014)

Expression of neutrophil gelatinase-associated lipocalin (NGAL) in the gut in Crohn’s disease
por: Thorsvik, Silje, et al.
Publicado: (2018)

Survival benefit of neoadjuvant chemotherapy for resectable breast cancer: A meta-analysis
por: Chen, Yan, et al.
Publicado: (2018)

Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases
por: Ichida, Hirofumi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5i73reom29uk9c1ut5r9scp44p